← All trials
NCT05582629
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Oct 21, 2022
- Primary completion
- Apr 30, 2023
- Completion date
- May 30, 2023
- First posted
- Oct 17, 2022
- Last posted
- Nov 22, 2022
- Enrollment
- 1200
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Government of ChinaLead sponsor
- Sponsor GmbHCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.